Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMPFN6Y)

Drug Name
Olanzapine Drug Info
Synonyms
Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
135398745
ChEBI ID
CHEMBL715
CAS Number
CAS 132539-06-1
TTD Drug ID
D0V4QS
VARIDT Drug ID
DR00462
INTEDE Drug ID
DR1186
ACDINA Drug ID
D00484

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 2.37 0.00e+0 52/108 (48.15%) DKC1;RPP40;NOP56;...
DNA replication 2.13 0.00e+0 34/36 (94.44%) MCM3;FEN1;MCM5;...
Spliceosome 2.11 0.00e+0 101/150 (67.33%) PRPF19;HSPA8;PRPF3;...
Base excision repair 1.98 2.88e-3 29/33 (87.88%) FEN1;NTHL1;PARP2;...
One carbon pool by folate 1.97 2.30e-3 15/20 (75%) SHMT2;MTHFD2;ATIC;...
RNA transport 1.96 1.92e-3 128/186 (68.82%) RNPS1;TACC3;ELAC2;...
Fanconi anemia pathway 1.91 4.11e-3 36/54 (66.67%) REV1;RAD51C;MLH1;...
Mismatch repair 1.75 1.58e-2 22/23 (95.65%) MLH1;RFC5;RPA1;...
Cell cycle 1.72 2.05e-2 110/124 (88.71%) MYC;MCM3;PLK1;...
Oocyte meiosis 1.70 2.48e-2 90/129 (69.77%) PLK1;SMC1A;ADCY9;...
Homologous recombination 1.68 2.62e-2 35/41 (85.37%) BABAM1;RAD51C;BRCA1;...
Aminoacyl-tRNA biosynthesis 1.65 3.41e-2 15/66 (22.73%) FARSA;LARS2;NARS2;...
Galactose metabolism -1.67 3.56e-2 26/31 (83.87%) PFKP;LALBA;SI;...
Inflammatory bowel disease -1.67 3.17e-2 58/65 (89.23%) RELA;HLA-DPB1;IFNGR2;...
Renin secretion -1.72 1.88e-2 61/69 (88.41%) PLCB1;CLCA4;PPP3CB;...
Human cytomegalovirus infection -1.72 1.85e-2 201/225 (89.33%) CDKN1A;BID;SOS2;...
Rap1 signaling pathway -1.75 1.35e-2 184/210 (87.62%) LCP2;MAPK1;INS;...
Carbohydrate digestion and absorption -1.75 1.30e-2 37/47 (78.72%) SLC5A1;ATP1B2;SI;...
Phospholipase D signaling pathway -1.79 8.45e-3 134/148 (90.54%) AGPAT1;RAPGEF3;PLD1;...
Amoebiasis -1.80 8.23e-3 99/102 (97.06%) GNAL;SERPINB3;COL4A5;...
Neutrophil extracellular trap formation -1.80 8.60e-3 101/189 (53.44%) MAPK11;PLCG1;FGA;...
Proximal tubule bicarbonate reclamation -1.83 5.79e-3 21/23 (91.3%) MDH1;ATP1B2;PCK1;...
Lipid and atherosclerosis -1.83 5.41e-3 190/215 (88.37%) ERN1;MAPK11;PLCG1;...
Antigen processing and presentation -1.84 5.69e-3 60/78 (76.92%) CTSS;KLRD1;HLA-A;...
Staphylococcus aureus infection -1.84 6.01e-3 72/95 (75.79%) PTAFR;CFD;FPR1;...
Legionellosis -1.85 3.98e-3 51/57 (89.47%) IL6;TLR5;IL18;...
NF-kappa B signaling pathway -1.86 4.22e-3 90/104 (86.54%) CD14;GADD45A;TNF;...
Type I diabetes mellitus -1.90 2.70e-3 38/43 (88.37%) HSPD1;TNF;PTPRN2;...
Kaposi sarcoma-associated herpesvirus infection -1.90 1.93e-3 172/193 (89.12%) IFNAR1;IL6;TCF7L1;...
Chemokine signaling pathway -1.91 2.08e-3 163/192 (84.9%) PLCG1;GNG7;STAT3;...
Hematopoietic cell lineage -1.94 1.13e-3 90/99 (90.91%) CD7;HLA-DPB1;CD1D;...
Natural killer cell mediated cytotoxicity -1.94 1.23e-3 99/131 (75.57%) KIR2DL1;LCK;KIR2DL3;...
Fc epsilon RI signaling pathway -1.94 1.35e-3 57/68 (83.82%) MAPK11;PLCG1;MAP2K3;...
Autoimmune thyroid disease -2.00 1.50e-3 46/53 (86.79%) HLA-A;HLA-F;GZMB;...
Intestinal immune network for IgA production -2.08 0.00e+0 38/48 (79.17%) ICOS;HLA-DPB1;IL15RA;...
TNF signaling pathway -2.09 0.00e+0 103/112 (91.96%) CREB5;CREB3L1;ATF2;...
Graft-versus-host disease -2.10 0.00e+0 32/42 (76.19%) HLA-DPA1;HLA-C;CD28;...
Viral protein interaction with cytokine and cytokine re... -2.11 0.00e+0 84/100 (84%) PF4;PPBP;CSF1;...
IL-17 signaling pathway -2.15 0.00e+0 84/94 (89.36%) MAPK3;MUC5AC;CXCL6;...
Allograft rejection -2.15 0.00e+0 32/38 (84.21%) TNF;HLA-A;HLA-F;...
Rheumatoid arthritis -2.18 0.00e+0 78/93 (83.87%) CSF1;TCIRG1;TNF;...
Asthma -2.36 0.00e+0 25/31 (80.65%) EPX;HLA-DRA;FCER1G;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.03uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H